U.S. markets closed
  • S&P 500

    3,791.05
    +112.62 (+3.06%)
     
  • Dow 30

    30,316.98
    +826.09 (+2.80%)
     
  • Nasdaq

    11,176.41
    +360.97 (+3.34%)
     
  • Russell 2000

    1,766.76
    +57.89 (+3.39%)
     
  • Crude Oil

    86.25
    +2.62 (+3.13%)
     
  • Gold

    1,733.80
    +31.80 (+1.87%)
     
  • Silver

    21.08
    +0.49 (+2.38%)
     
  • EUR/USD

    0.9991
    +0.0164 (+1.67%)
     
  • 10-Yr Bond

    3.6170
    -0.0340 (-0.93%)
     
  • GBP/USD

    1.1475
    +0.0156 (+1.38%)
     
  • USD/JPY

    144.0160
    -0.6040 (-0.42%)
     
  • BTC-USD

    20,205.30
    +681.48 (+3.49%)
     
  • CMC Crypto 200

    458.29
    +12.85 (+2.88%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Oxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year ago

·3 min read

The nature of investing is that you win some, and you lose some. Anyone who held Oxford Biomedica plc (LON:OXB) over the last year knows what a loser feels like. In that relatively short period, the share price has plunged 66%. At least the damage isn't so bad if you look at the last three years, since the stock is down 25% in that time.

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

Check out our latest analysis for Oxford Biomedica

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Oxford Biomedica managed to increase earnings per share from a loss to a profit, over the last 12 months.

Earnings per share growth rates aren't particularly useful for comparing with the share price, when a company has moved from loss to profit. So it makes sense to check out some other factors.

Oxford Biomedica's revenue is actually up 63% over the last year. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for Oxford Biomedica in this interactive graph of future profit estimates.

A Different Perspective

While the broader market lost about 3.6% in the twelve months, Oxford Biomedica shareholders did even worse, losing 66%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 1.9%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Oxford Biomedica has 2 warning signs (and 1 which is a bit concerning) we think you should know about.

Oxford Biomedica is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here